Table 3 summarizes both ongoing and completed clinical trials investigating the potential of CAR-NK-cell therapy. These trials are examining critical aspects of CAR-NK therapy, including response rates, durability, and potential adverse effects. The first clinical trial of CAR-NK therapy for solid tumours used MUC1 (Mucin 1) CAR-NK cells to target malignant solid tumours, including glioblastoma, pancreatic, colorectal, breast, and ovarian cancers (NCT02839954) and was quite promising, with seven out of eight patients achieving stable disease without serious side effects [122]. This evidence concerns the gene MUC1 and ovarian cancer.